PTH and cancer: PTH levels ≥47 pg/mL (PTH+ group) at any time within the first 5 years following the cancer diagnosis were associated with significantly inferior EFS in the groups: embryonal malignancies, lymphatic malignancies, and malignant primary brain tumors (see below and Fig. 1B).